2-(benzyloxy)-5-(trifluoromethyl)benzoic acid | 53985-54-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(benzyloxy)-5-(trifluoromethyl)benzoic acid
• 英文别名: 2-[(phenylmethyl)oxy]-5-(trifluoromethyl)benzoic acid；2-benzyloxy-5-trifluoromethylbenzoic acid；2-Benzyloxy-5-trifluormethyl-benzoesaeure；2-Benzyloxy-5-trifluormethylbenzoesaeure；2-benzyloxy-5-trifluormethylbenzoic acid；2-phenylmethoxy-5-(trifluoromethyl)benzoic acid
• CAS: 53985-54-9
• 化学式: C₁₅H₁₁F₃O₃
• 分子量: 296.246
• InChiKey: HWGYOFVHXMEEJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(benzyloxy)-5-(trifluoromethyl)benzoic acid 在 sodium hydroxide 作用下， 以 水 为溶剂， 生成 2-Benzyloxy-5-trifluoromethylbenzoic Acid Sodium Salt
  参考文献：
  名称：

  Substituted benzoic acid hypolipemic agents

  摘要：

  多取代苯甲酸及其在哺乳动物中作为降血脂剂的应用。

  公开号：

  US03953595A1
• 作为产物：
  描述：

  2-羟基-5-三氟甲基苯甲酸 在 potassium carbonate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 水 、 丙酮 为溶剂， 反应 6.0h， 生成 2-(benzyloxy)-5-(trifluoromethyl)benzoic acid
  参考文献：
  名称：

  5-Substituted-N-pyridazinylbenzamides as potent and selective LRRK2 inhibitors: Improved brain unbound fraction enables efficacy

  摘要：

  We describe the discovery and optimization of 5-substituted-N-pyridazinylbenzamide derivatives as potent and selective LRRK2 inhibitors. Extensive SAR studies led to the identification of compounds 18 and 23, which demonstrated good in vitro pharmacokinetic profile and excellent selectivity over 140 other kinases. Both compounds demonstrated high unbound fractions in both blood and brain. Compound 18 proved to be brain penetrant, and the high unbound fraction of compound 18 in brain enabled its in vivo efficacy in CNS, wherein a significant inhibition of LRRK2 Ser935 phosphorylation was observed in rat brain following intravenous infusion at 5 mg/kg/h.

  DOI：

  10.1016/j.bmcl.2018.11.054

文献信息

• Compounds
  申请人：Barber Gordon Christopher

  公开号：US20050020611A1

  公开（公告）日：2005-01-27

  This invention relates to nicotinamide derivatives of general formula (I): in which R 1 , Z and R 2 have the meanings defined herein, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of such derivatives.

  这项发明涉及一般式(I)的烟酰胺衍生物： 其中R1、Z和R2具有本文所定义的含义，并涉及用于制备、用于制备的中间体、含有和使用这种衍生物的组合物的过程。
• Benzamide derivatives
  申请人：May & Baker Limited

  公开号：US04146631A1

  公开（公告）日：1979-03-27

  Benzamide derivatives of the formula:- ##STR1## wherein R.sup.1 represents a fluorine, chlorine or bromine atom, or an alkyl, alkoxy, alkylthio, alkylsulphonyl, alkanoylamino, alkylamino or alkylsulphamoyl group, each such group containing from 1 to 6 carbon atoms, a dialkylsulphamoyl, dialkylamino or dialkylcarbamoyl group (wherein the two alkyl groups may be the same or different and each contains from 1 to 4 carbon atoms), an alkanoyl, alkoxycarbonyl, alkoxycarbonylamino or alkylcarbamoyl group containing from 2 to 6 carbon atoms, or a hydroxy, formyl, nitro, trifluoromethyl, aryl, benzyloxycarbonylamino, amino, sulphamoyl, cyano, tetrazol-5-yl, carboxy, carbamoyl or aroyl group, and n represents an integer 1, 2 or 3, are new compounds possessing pharmacological properties, in particular properties of value in the treatment of respiratory disorders manifested by the interaction of tissue-fixed antibodies with specific antigens.

  Benzamide衍生物的公式为：-##STR1##其中R.sup.1代表氟、氯或溴原子，或者是含有1到6个碳原子的烷基、烷氧基、烷硫基、烷基磺酰、烷酰胺基、烷基氨基或烷基磺酰胺基的基团，或者是含有2到6个碳原子的二烷基磺酰胺基、二烷基氨基或二烷基氨基甲酰基（其中两个烷基可能相同或不同，每个烷基都含有1到4个碳原子），或者是含有2到6个碳原子的烷酰基、烷氧羰基、烷氧羰基胺基或烷基甲酰胺基的基团，或者是羟基、甲酰基、硝基、三氟甲基、芳基、苄氧羰基胺基、氨基、磺酰基、氰基、四唑-5-基、羧基、氨基甲酰基或芳酰基基团，n表示整数1、2或3，是具有药理学特性的新化合物，特别是在治疗通过组织固定抗体与特定抗原相互作用表现出的呼吸系统疾病方面具有价值的特性。
• Nicotinamide derivatives useful as pde4 inhibitors
  申请人：Barber Gordon Christopher

  公开号：US20060178408A1

  公开（公告）日：2006-08-10

  This invention relates to nicotinamide derivatives of general formula (I): in which R 1 , Z and R 2 have the meanings defined herein, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of such derivatives.

  本发明涉及通式（I）的烟酰胺衍生物，其中R1，Z和R2具有在此定义的含义，并涉及用于制备、制备中间体、含有和使用这种衍生物的组合物的过程。
• Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders
  申请人：Bit Rino Antonio

  公开号：US20080207708A1

  公开（公告）日：2008-08-28

  Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein X, Z, Y′, Y″, R 1 , R 2a , R 2b , and R x are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

  化合物的公式(I)或其药学上可接受的衍生物：其中X，Z，Y'，Y''，R1，R2a，R2b和Rx如规范中定义，制备这种化合物的过程，包含这种化合物的制药组合物以及在医学中使用这种化合物的用途。
• Synthesis and quantitative structure-activity relationships of antiallergic 2-hydroxy-N-(1H-tetrazol-5-yl)benzamides and N-(2-hydroxyphenyl)-1H-tetrazole-5-carboxamides
  作者：Roger E. Ford、Phillip Knowles、Edward Lunt、Stuart M. Marshall、Audrey J. Penrose、Christopher A. Ramsden、Anthony J. H. Summers、Joyce L. Walker、Derek E. Wright

  DOI：10.1021/jm00154a019

  日期：1986.4

  The synthesis and antiallergic activity of a series of 2-hydroxy-N-1H-tetrazol-5-ylbenzamides and isomeric N-(2-hydroxyphenyl)-1H-tetrazole-5-carboxamides is described. A relationship between structure and intravenous antiallergic activity in the rat passive cutaneous anaphylaxis (PCA) test has been established using a Hansch/Free-Wilson model and used to direct studies toward potent derivatives. The contribution of physicochemical properties to activity is discussed. One member of this series, N-(3-acetyl-5-fluoro-2-hydroxyphenyl)-1H-tetrazole-5-carboxamide (3f), which was selected for further evaluation, has an ID50 value of 0.16 mg/kg po and is 130 times more potent than disodium cromoglycate (DSCG) on intravenous administration.